INABIN8BIO, INC.

Nasdaq in8bio.com


$ 1.10 $ -0.59 (-35.12 %)    

Friday, 14-Jun-2024 15:59:42 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 1.09
$ 1.51
$ 0.00 x 0
$ 0.00 x 0
$ 1.09 - $ 1.51
$ 0.65 - $ 2.48
4,916,800
na
47.18M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 09-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jones-trading-maintains-buy-on-in8bio-raises-price-target-to-65

Jones Trading analyst Soumit Roy maintains IN8bio (NASDAQ:INAB) with a Buy and raises the price target from $5 to $6.5.

 hc-wainwright--co-reiterates-buy-on-in8bio-maintains-125-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $12.5 price ...

 in8bio-presents-phase-1-inb-100-trial-data-at-eha-2024-100-of-evaluable-leukemia-patients-remain-alive-progression-free-and-in-durable-cr-through-one-year-demonstrates-in-vivo-expansion-and-persistence-of-haplo-matched-allogeneic-gamma-delta-t-cell-therapy

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapse...

 hc-wainwright--co-reiterates-buy-on-in8bio-maintains-125-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $12.5 price ...

 in8bio-presents-data-on-gamma-delta-t-cell-therapy-for-glioblastoma-at-asco-2024

 IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies...

 in8bio-reports-upcoming-presentation-of-updated-results-from-its-fully-enrolled-phase-1-study-of-inb-200-at-asco-meeting

INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a p...

 in8bio-showcases-reproducible-gamma-delta-t-cell-therapy-manufacturing-in-oral-presentation-at-asgct-2024

IN8bio (NASDAQ:INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented i...

 hc-wainwright--co-maintains-buy-on-in8bio-lowers-price-target-to-125

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains IN8bio (NASDAQ:INAB) with a Buy and lowers the price target...

 in8bio-q1-2024-gaap-eps-020-misses-018-estimate

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 1...

 hc-wainwright--co-reiterates-buy-on-in8bio-maintains-14-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:INAB) with a Buy and maintains $14 price ta...

 kill-leukemia-cells-while-preserving-healthy-tissues-nano-cap-cancer-focused-firm-in8bios-preclinical-candidate-shows-potential

IN8bio's nsCAR platform, INB-300. Presented at AACR 2024, new preclinical data highlights its superior selectivity in targe...

 why-pricesmart-shares-are-trading-higher-by-around-5-here-are-20-stocks-moving-premarket

Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expecte...